Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue vs. Oral Methotrexate and Single vs. Double Delayed Intensification for Children with Standard Risk Acute Lymphoblastic Leukemia - A Phase III Study Limited to Former CCG Institutions - CCG-1991

Next Previous
X
Search
Trial Profile

Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue vs. Oral Methotrexate and Single vs. Double Delayed Intensification for Children with Standard Risk Acute Lymphoblastic Leukemia - A Phase III Study Limited to Former CCG Institutions - CCG-1991

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Mercaptopurine; Methotrexate; Methotrexate; Pegaspargase; Tioguanine; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Feb 2016 Biomarkers information updated
    • 18 Oct 2013 Event free survival tagged as primary as per CT.gov.
    • 12 Sep 2013 Planned End Date changed from 1 Jun 2000 to 1 Nov 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top